News | March 24, 2010

Moderate Hypofractionated Treatment with Chemotherapy Shows Low Side Effects

March 24, 2010 - A moderately aggressive hypofractionation schedule can be used along with chemotherapy, with low side effects, according to the first published results from a study on the concurrent use of hypofractionated TomoTherapy radiation treatments and chemotherapy for unresectable locally-advanced non-small cell lung cancer (NSCLC).

The Department of Radiation Oncology at the Universitaire Ziekenhuis (UZ) Brussel in Brussels, Belgium, conducted the trial, results of which were published in the journal Cancer (Volume 116, Issue 1, Pages 241-250, Jan 2010).

Previous studies have shown an increase in the rate of tumor control via either escalating biologically effective radiation dose or the addition of chemotherapy concurrent with the course of radiation. This trial tests the feasibility of dose escalation along with concurrent chemotherapy, taking advantage of the accuracy and dose conformity of helical TomoTherapy treatments in minimizing radiation damage to normal tissues.

The study focused on stage III non-small cell lung cancer. Various strategies have been tried to improve outcomes for later stage lung cancer, including increasing dose by increasing the number of fractions (with conventional fractionation of ~2 Gy/fx), increasing dose by increasing fraction size (hypofractionation of up to ~3 Gy/fx), and using chemotherapy at the same time as radiation ("concurrent" chemotherapy).

Increasing the number of fractions has been shown to be of limited benefit because of the lengthening of the overall treatment course and consequent tumor repopulation. Concurrent chemotherapy with conventional fractionation is the standard of care in the United States, after clinical trials showing improved survival over giving chemo either before or after the course of radiation, but it means that the patient will be more likely to incur side effects for a given radiation dose because of an additive effect. Hypofractionation even without concurrent chemo has been shown to be promising in terms of survival. But researchers found in this study that a moderately aggressive hypofractionation schedule can be used along with chemotherapy, with low side effects.

Tomotherapy said that a larger phase II study being started by UZB will add to the evidence that this mode of treatment is safe and effective.

For the complete study: http://www3.interscience.wiley.com/cgi-bin/fulltext/122684509/HTMLSTART?...

For more information: www.tomotherapy.com

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init